ATAI Life Sciences N.V. Forecast, price target & analysts
ATAI Life Sciences N.V. Target price 2025 - Analyst rating & recommendation
ATAI Life Sciences N.V. Classifications & Recommendation:
ATAI Life Sciences N.V. Price Target
| Target Price | $7.40 |
| Price | $1.21 |
| Potential |
511.57%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target ATAI Life Sciences N.V. 2026 .
The average ATAI Life Sciences N.V. target price is $7.40.
This is
511.57%
register free of charge
$11.00
809.09%
register free of charge
$5.00
313.22%
register free of charge
|
|
| A rating was issued by 8 analysts: 8 Analysts recommend ATAI Life Sciences N.V. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ATAI Life Sciences N.V. stock has an average upside potential 2026 of
511.57%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 0.31 | 0.25 |
| 0.00% | 19.35% | |
| EBITDA Margin | -32,974.19% | -50,440.00% |
| 18.32% | 52.97% | |
| Net Margin | -50,346.00% | -42,693.41% |
| 272.00% | 15.20% |
6 Analysts have issued a sales forecast ATAI Life Sciences N.V. 2025 . The average ATAI Life Sciences N.V. sales estimate is
This results in the following potential growth metrics:
2 Analysts have issued an ATAI Life Sciences N.V. EBITDA forecast 2025. The average ATAI Life Sciences N.V. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
5 ATAI Life Sciences N.V. Analysts have issued a net profit forecast 2025. The average ATAI Life Sciences N.V. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.93 | -0.64 |
| 272.00% | 31.18% | |
| P/E | negative | |
| EV/Sales | 653.76 |
5 Analysts have issued a ATAI Life Sciences N.V. forecast for earnings per share. The average ATAI Life Sciences N.V. EPS is
This results in the following potential growth metrics and future valuations:
ATAI Life Sciences N.V....
Current ATAI Life Sciences N.V. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 19 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 13 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 29 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 28 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 18 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 30 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 19 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 13 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 29 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 28 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 18 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 30 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
